Abstract
Glutamine metabolism is largely controlled by two enzyme pathways: 1) Conversion of glutamine to glutamate catalyzed by glutaminases, followed by conversion of glutamate to α-ketoglutarate by a glutamate-linked aminotransferases (or by the action of glutamate dehydrogenase); and 2) conversion of glutamine to α-ketoglutaramate (KGM) catalyzed by glutamine-utilizing transaminases (aminotransferases), followed by conversion of KGM to α-ketoglutarate by the action of ω-amidase. The former pathway has been well documented and intensively studied for over 60 years, whereas only recently has research focused on the latter pathway, its importance in homeostasis and the control of anaplerotic metabolites. The glutamine transaminases are of fundamental importance 1) as repair enzymes (salvage of α-keto acids), 2) in nitrogen and sulfur homeostasis (closure of the methionine salvage pathway), 3) in 1-carbon metabolism, and 4) in metabolism of seleno amino acids. As a result of their broad substrate specificity the two principal mammalian glutamine transaminases (i.e. glutamine transaminases L and K) have also been characterized as kynurenine aminotransferases (KAT I and KAT III, respectively), responsible for the production of neuroactive kynurenate. The glutamine transaminases are also active with a variety of sulfur- and selenium-containing amino acids. Some of the products derived from the transamination of these amino acids may also be neuroactive (e.g. certain sulfur-containing cyclic ketimines) as well as chemopreventive (e.g. the α-keto acids derived from seleno amino acids). Of relevance to human health and disease, the glutamine transaminases may contribute to the bioactivation (toxification) of halogenated alkenes (and possibly other xenobiotic electrophiles), some of which are environmental contaminants. Finally, the role of the glutamine transaminases and ω-amidase in cancer biology has been little studied. However, the “glutamine addiction” of many tumors suggests that the glutamine transaminases together with ω-amidase may have a fundamental and influential role in regulating cancer progression
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Meister A, Sober HA, Tice SV, Fraser PE. Transamination and associated deamidation of asparagine and glutamine. J Biol Chem. 1952;197:319–30.
Cooper AJL, Meister A. Isolation and properties of a new glutamine transaminase from rat kidney. J Biol Chem. 1974;249:2554–61.
Han Q, Li J, Li J. pH dependence, substrate specificity and inhibition of human kynurenine aminotransferase I. Eur J Biochem. 2004;71:4804–14.
Han Q, Robinson H, Cai T, Tagle DA, Li J. Biochemical and structural properties of mouse kynurenine aminotransferase III. Mol Cell Biol. 2009;29:784–93.
Pinto JT, Krasnikov BF, Alcutt S, Jones ME, Dorai T, Villar MT, Artigues A, Li J, Cooper AJL. Kynurenine aminotransferase III and glutamine transaminase L are identical Enzymes that have cysteine Sconjugate β-lyase activity and can transaminate L-selenomethionine. J Biol Chem. 2014;289:30950–61.
Han Q, Cai T, Tagle DA, Robinson H, Li J. Substrate specificity and structure of human aminoadipate aminotransferase/kynurenine aminotransferase II. Biosci Rep. 2008;28:205–15.
Cooper AJL, Meister A. Comparative studies of glutamine transaminases from rat tissues. Comp Biochem Physiol. 1981;69B:137–45.
Hersh LB. Rat liver ω-amidase: purification and properties. Biochemistry. 1971;10:2884–91.
Jaisson S, Veiga-da-Cunha M, Van Schaftingen E. Molecular identification of ω-amidase, the enzyme that is functionally coupled with glutamine transaminases, as the putative tumor suppressor Nit2. Biochimie. 2009;91:1066–71.
Krasnikov BF, Chien C-H, Nostramo R, Pinto JT, Nieves E, Callaway M, Sun J, Huebner K, Cooper AJL. Identification of the putative tumor suppressor Nit2 as ω-amidase, an enzyme metabolically linked to glutamine and asparagine transamination. Biochimie. 2009;91:1072–80.
Chien CH, Gao QZ, Cooper AJL, Lyu JH, Sheu SY. Structural insights into the catalytic active site and activity of human Nit2/ω-amidase: kinetic assay and molecular dynamics simulation. J Biol Chem. 2012;287:25715–26.
Cooper AJL. The role of glutamine transaminase K (GTK) in sulfur and α-keto acid metabolism in the brain, and possible bioactivation of neurotoxicants. Neurochem Int. 2004;44:557–77.
Darmaun D, Matthews DE, Bier DM. Glutamine and glutamate kinetics in humans. Am J Physiol. 1986;251:E117–26.
Miller JE, Litwack G. Purification, properties, and identity of liver mitochondrial tyrosine aminotransferase. J Biol Chem. 1971;246:3234–40.
Wray JW, Abeles RH. The methionine salvage pathway in Klebsiella pneumoniae and rat liver. Identification and characterization of two novel dioxygenases. J Biol Chem. 1995;270:3147–53.
Jones TW, Qin C, Schaeffer VH, Stevens JL. Immunohistochemical localization of glutamine transaminase K, a rat kidney cysteine conjugate β-lyase, and the relationship to the segment specificity of cysteine conjugate nephrotoxicity. Mol Pharmacol. 1988;34:621–7.
Cooper AJL, Abraham DG, Gelbard AS, Lai JC, Petito CK. High activities of glutamine transaminase K (dichlorovinylcysteine β-lyase) and ω-amidase in the choroid plexus of rat brain. J Neurochem. 1993;61:1731–41.
Lin CH, Chung MY, Chen WB, Chien CH. Growth inhibitory effect of the human NIT2 gene and its allelic imbalance in cancers. FEBS J. 2007;274:2946–56.
Wipf D, Ludewig U, Tegeder M, Rentsch D, Koch W, Frommer WB. Conservation of amino acid transporters in fungi, plants and animals. Trends Biochem Sci. 2002;27:139–47.
Patel TB, Waymack PP, Olson MS. The effect of the monocarboxylate translocator inhibitor, α-cyanocinnamate, on the oxidation of branched chain α-keto acids in rat liver. Arch Biochem Biophys. 1980;201:629–35.
Steele RD. Blood-brain barrier transport of the α-keto acid analogs of amino acids. Fed Proc. 1986;45:2060–4.
Hutson SM, Rannels SL. Characterization of a mitochondrial transport system for branched chain α-keto acids. J Biol Chem. 1985;260:14189–93.
Hoffer LJ, Taveroff A, Robitaille L, Mamer OA, Reimer ML. α-Keto and α-hydroxy branched-chain acid interrelationships in normal humans. J Nutr. 1993;123:1513–21.
Pace HC, Brenner C. The nitrilase superfamily: classification, structure and function. Genome Biol. 2001;2(1):REVIEWS0001.
Huebner K, Saldivar JC, Sun J, Shibata H, Druck T. Hits, fhits and nits: beyond enzymatic function. Adv Enzyme Regul. 2011;51:208–17.
Zielke HR, Ozand PT, Tildon JT, Sevdalian DA, Cornblath M. Reciprocal regulation of glucose and glutamine utilization by cultured human diploid fibroblasts. J Cell Physiol. 1978;95:41–8.
Roediger WE. Utilization of nutrients by isolated epithelial cells of the rat colon. Gastroenterology. 1982;83:424–9.
Mallet RT, Kelleher JK, Jackson MJ. Substrate metabolism of isolated jejunal epithelium: conservation of three-carbon units. Am J Physiol. 1986;250:C191–8.
Abou-Khalil WH, Yunis AA, Abou-Khalil S. Prominent glutamine oxidation activity in mitochondria of hematopoietic tumors. Cancer Res. 1983;43:1990–3.
Erickson JW, Cerione RA. Glutaminase: a hot spot for regulation of cancer cell metabolism? Oncotarget. 2010;1:734–40.
Koppenol WH, Bounds PL, Dang CV. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11:325–37.
Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21:297–308.
Miles EW. Pyridoxal phosphate enzymes catalyzing β-elimination and β-replacement reactions. In: Dolphin D, Poulson R, Avramović O, editors. Vitamin B6 pyridoxal phosphate part B. New York, NY: John Wiley and Sons; 1986. p. 253–310.
Ueno H, Likos JJ, Metzler DE. Chemistry of the inactivation of cytosolic aspartate aminotransferase by serine O-sulfate. Biochemistry. 1982;21:4387–93.
Adams B, Lowpetch K, Thorndycroft F, Whyte SM, Young DW. Stereochemistry of reactions of the inhibitor/substrates L- and D-β-chloroalanine with β-mercaptoethanol catalysed by L-aspartate aminotransferase and D-amino acid aminotransferase respectively. Org Biomol Chem. 2005;3:3357–64.
Dekant W, Vamvakas S, Anders MW. Formation and fate of nephrotoxic and cytotoxic glutathione S-conjugates: cysteine conjugate β-lyase pathway. Adv Pharmacol. 1994;27:115–62.
Anders MW. Chemical toxicology of reactive intermediates formed by the glutathione-dependent bioactivation of halogen-containing compounds. Chem Res Toxicol. 2008;21:145–59.
Cooper AJL, Pinto JT. Role of cysteine S-conjugate β-lyases in the bioactivation of renal toxicants. In: Elfarra AA, editor. Biotechnology: pharmaceutical aspects. Advances in bioactivation research. New York, NY: Springer; 2008. p. 323–46.
Cooper AJL, Krasnikov BF, Niatsetskaya ZV, Pinto JT, Callery PS, Villar MT, Artigues A, Bruschi SA. Cysteine S-conjugate β-lyases: Important roles in the metabolism of naturally occurring sulfur and selenium-containing compounds, xenobiotics and anticancer agents. Amino Acids. 2011;7:7–27.
Stevens JL, Robbins JD, Byrd RA. A purified cysteine conjugate β-lyase from rat kidney cytosol. Requirement for an α-keto acid or an amino acid oxidase for activity and identity with soluble glutamine transaminase K. J Biol Chem. 1986;261:15529–37.
Cavallini D, Ricci G, Duprè S, Pecci L, Costa M, Matarese RM, Pensa B, Antonucci A, Solinas SP, Fontana M. Sulfur-containing cyclic ketimines and imino acids. A novel family of endogenous products in the search for a role. Eur J Biochem. 1991;202:217–23.
Hallen A, Cooper AJL, Jamie JF, Haynes PA, Willows RD. Mammalian forebrain ketimine reductase identified as μ-crystallin; potential regulation by thyroid hormones. J Neurochem. 2011;118:379–87.
Hallen A, Jamie JF, Cooper AJL. Imine reductases: a comparison of glutamate dehydrogenase to ketimine reductases in the brain. Neurochem Res. 2013;39(3):527–41.
Commandeur JNM, Andreadou I, Rooseboom M, Out M, de Leur LJ, Groot E, Vermeulen NPE. Bioactivation of selenocysteine Se-conjugates by a highly purified rat renal cysteine conjugate β-lyase/glutamine transaminase K. J Pharmacol Exp Ther. 2000;294:753–61.
Nian H, Bisson WH, Dashwood WM, Pinto JT, Dashwood RH. α-Keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells. Carcinogenesis. 2009;30:1416–23.
Pinto JT, Lee JI, Sinha R, MacEwan ME, Cooper AJL. Chemopreventive mechanisms of α-keto acid metabolites of naturally occurring organoselenium compounds. Amino Acids. 2011;41:29–41.
Cooper AJL, Pinto JT, Krasnikov BF, Niatsetskaya ZV, Han Q, Li J, Vauzour D, Spencer JPE. Substrate specificity of human glutamine transaminase K as an aminotransferase and as a cysteine S-conjugate β-lyase. Arch Biochem Biophys. 2008;474:72–81.
Suzuki KT, Tsuji Y, Ohta Y, Suzuki N. Preferential organ distribution of methylselenol source Se-methylselenocysteine relative to methylseleninic acid. Toxicol Appl Pharmacol. 2008;227:76–83.
Okuno T, Motobayashi S, Ueno H, Nakamuro K. Identification of mouse selenomethionine α, γ-elimination enzyme: cystathionine γ-lyase catalyzes its reaction to generate methylselenol. Biol Trace Elem Res. 2005;108:245–57.
Cooper AJL, Pinto JT. Aminotransferase, L-amino acid oxidase and β-lyase reactions involving L-cysteine S-conjugates found in allium extracts. Relevance to biological activity? Biochem Pharmacol. 2005;69:209–20.
Lee JI, Nian H, Cooper AJ, Sinha R, Dai J, Bisson WH, Dashwood RH, Pinto JT. α-Keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells. Cancer Prev Res. 2009;2:683–93.
Acknowledgements
Part of the work from our laboratories cited in this chapter was supported by NIH grants CA111842 (to JTP) and ES008421 (to AJLC).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Cooper, A.J.L. et al. (2015). Role of Glutamine Transaminases in Nitrogen, Sulfur, Selenium, and 1-Carbon Metabolism. In: Rajendram, R., Preedy, V., Patel, V. (eds) Glutamine in Clinical Nutrition. Nutrition and Health. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1932-1_3
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1932-1_3
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-1931-4
Online ISBN: 978-1-4939-1932-1
eBook Packages: MedicineMedicine (R0)